130 249

Cited 0 times in

Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial

Authors
 Youn Kyung Kee  ;  Sang Youb Han  ;  Duk Hee Kang  ;  Jung Woo Noh  ;  Kyung Hwan Jeong  ;  Gheun Ho Kim  ;  Yang Wook Kim  ;  Beom Seok Kim 
Citation
 YONSEI MEDICAL JOURNAL, Vol.62(1) : 41-49, 2021-01 
Journal Title
YONSEI MEDICAL JOURNAL
ISSN
 0513-5796 
Issue Date
2021-01
MeSH
Adsorption ; Carbon / administration & dosage ; Carbon / therapeutic use ; Creatinine / blood ; Cross-Over Studies ; Cystatin C / blood ; Disease Progression ; Female ; Glomerular Filtration Rate / drug effects ; Humans ; Indican / blood ; Male ; Middle Aged ; Oxides / administration & dosage ; Oxides / therapeutic use ; Renal Insufficiency, Chronic / blood ; Renal Insufficiency, Chronic / drug therapy* ; Renal Insufficiency, Chronic / physiopathology ; Treatment Outcome
Keywords
AST-120 ; Chronic kidney disease ; DW-7202 ; adherence ; preference
Abstract
Purpose: Oral adsorbents delay disease progression and improve uremic symptoms in patients with chronic kidney disease (CKD). DW-7202 is a newly developed oral adsorbent with high adsorptive selectivity for uremic toxins. We evaluated patient preference for and adherence to DW-7202 versus AST-120 therapy and compared treatment efficacy and safety in patients with pre-dialysis CKD.

Materials and methods: A seven-center, randomized, open-label, two-way crossover, active-controlled, phase IV clinical trial was conducted. Patients with stable CKD were randomly assigned to receive DW-7202 (capsule type) or AST-120 (granule type) for 12 weeks. The groups then switched to the other adsorbent and took it for the next 12 weeks. Patient preference was the primary outcome. Secondary outcomes included changes in estimated glomerular filtration rate (eGFR) and serum creatinine, cystatin C, and indoxyl sulfate (IS) levels.

Results: Significantly more patients preferred DW-7202 than AST-120 (p<0.001). Patient adherence improved after switching from AST-120 to DW-7202; there was no apparent change in adherence after switching from DW-7202 to AST-120. Changes in eGFR and serum creatinine, cystatin C, and IS levels were not significantly different according to adsorbent type. There was also no significant difference in the incidences of adverse events during treatment with DW-7202 and AST-120.

Conclusion: DW-7202 can be considered as an alternative to AST-120 in patients who cannot tolerate or show poor adherence to granule type adsorbents. Further studies to evaluate factors affecting patient preferences and improved adherence are warranted (Clinical trial registration No. NCT02681952).
Files in This Item:
T202104808.pdf Download
DOI
10.3349/ymj.2021.62.1.41
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Beom Seok(김범석) ORCID logo https://orcid.org/0000-0002-5732-2583
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/186906
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links